Ani Pharmaceuticals (ANIP) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
ANIP ends flat (+0.0%) to $72.29. Closed at $72.29, +0.01% vs the prior close of $72.28. Day range $71.50–$73.08, opened at $72.65.
ANIP daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ANIP ends flat (+0.0%) to $72.29
- Closed at $72.29, +0.01% vs the prior close of $72.28. Day range $71.50–$73.08, opened at $72.65.
- Volume was 333.92K shares, 0.8x its 50-day average of 410.49K.
- Price is -2.0% vs its 50-day average ($73.73) and -7.4% vs its 200-day average ($78.04).
- 52-week range $69.58–$97.00; today's close sits at 10% of that range, 25.5% below the 52-week high.
Oct 15, 2026 — ANIP jumps 3.0% to $72.28
- Closed at $72.28, +3.02% vs the prior close of $70.16. Day range $71.02–$73.20, opened at $71.08.
- Volume was 241.00K shares, 0.6x its 50-day average of 409.78K — lighter than usual.
- Price is -2.2% vs its 50-day average ($73.94) and -7.4% vs its 200-day average ($78.08).
- 52-week range $69.58–$97.00; today's close sits at 10% of that range, 25.5% below the 52-week high.
Oct 14, 2026 — ANIP dips 1.0% to $70.16, a 52-week low, 3 down days in a row
- Closed at $70.16, -0.96% vs the prior close of $70.84. Day range $69.90–$72.31, opened at $70.54.
- Volume was 269.20K shares, 0.7x its 50-day average of 410.18K.
- Price is -5.3% vs its 50-day average ($74.09) and -10.2% vs its 200-day average ($78.12).
- 52-week range $69.58–$97.00; today's close sits at 2% of that range, 27.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ANIP slides 3.7% to $70.84
- Closed at $70.84, -3.74% vs the prior close of $73.59. Day range $70.44–$73.59, opened at $73.59.
- Volume was 331.80K shares, 0.8x its 50-day average of 412.19K.
- Price is -4.6% vs its 50-day average ($74.27) and -9.4% vs its 200-day average ($78.18).
- 52-week range $69.58–$97.00; today's close sits at 5% of that range, 27.0% below the 52-week high.
Oct 12, 2026 — ANIP dips 0.4% to $73.59
- Closed at $73.59, -0.41% vs the prior close of $73.89. Day range $72.80–$74.28, opened at $74.00.
- Volume was 318.50K shares, 0.8x its 50-day average of 409.93K.
- Price is -1.2% vs its 50-day average ($74.45) and -5.9% vs its 200-day average ($78.24).
- 52-week range $69.58–$97.00; today's close sits at 15% of that range, 24.1% below the 52-week high.
Oct 9, 2026 — ANIP rises 2.7% to $73.89, 3 up days in a row
- Closed at $73.89, +2.65% vs the prior close of $71.98. Day range $71.25–$74.43, opened at $71.87.
- Volume was 540.80K shares, 1.3x its 50-day average of 402.96K.
- Price is -0.9% vs its 50-day average ($74.57) and -5.6% vs its 200-day average ($78.28).
- 52-week range $69.58–$97.00; today's close sits at 16% of that range, 23.8% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — ANIP ends flat (+0.1%) to $71.98
- Closed at $71.98, +0.07% vs the prior close of $71.93. Day range $71.28–$73.01, opened at $71.84.
- Volume was 419.70K shares, 1.0x its 50-day average of 400.34K.
- Price is -3.6% vs its 50-day average ($74.70) and -8.1% vs its 200-day average ($78.31).
- 52-week range $69.58–$97.00; today's close sits at 9% of that range, 25.8% below the 52-week high.
Oct 7, 2026 — ANIP rises 0.6% to $71.93
- Closed at $71.93, +0.57% vs the prior close of $71.52. Day range $71.57–$72.74, opened at $71.77.
- Volume was 438.10K shares, 1.1x its 50-day average of 395.97K.
- Price is -4.0% vs its 50-day average ($74.89) and -8.2% vs its 200-day average ($78.36).
- 52-week range $69.58–$97.00; today's close sits at 9% of that range, 25.8% below the 52-week high.
Oct 6, 2026 — ANIP dips 1.5% to $71.52
- Closed at $71.52, -1.46% vs the prior close of $72.58. Day range $70.80–$72.99, opened at $72.99.
- Volume was 292.00K shares, 0.7x its 50-day average of 397.18K.
- Price is -4.7% vs its 50-day average ($75.07) and -8.8% vs its 200-day average ($78.42).
- 52-week range $69.58–$97.00; today's close sits at 7% of that range, 26.3% below the 52-week high.
Oct 5, 2026 — ANIP rises 0.6% to $72.58
- Closed at $72.58, +0.55% vs the prior close of $72.18. Day range $71.76–$73.40, opened at $72.57.
- Volume was 346.80K shares, 0.9x its 50-day average of 393.40K.
- Price is -3.5% vs its 50-day average ($75.21) and -7.5% vs its 200-day average ($78.47).
- 52-week range $69.58–$97.00; today's close sits at 11% of that range, 25.2% below the 52-week high.
Oct 2, 2026 — ANIP dips 1.1% to $72.18
- Closed at $72.18, -1.07% vs the prior close of $72.96. Day range $71.73–$73.27, opened at $73.16.
- Volume was 300.20K shares, 0.8x its 50-day average of 392.31K.
- Price is -4.2% vs its 50-day average ($75.31) and -8.1% vs its 200-day average ($78.51).
- 52-week range $69.58–$97.00; today's close sits at 9% of that range, 25.6% below the 52-week high.
ANIP latest news & SEC filings
Every SEC filing by or about ANIP in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lalwani Nikhil sold 5,400 shares at $71.89 (≈$388.21K) on Oct 15, 2026; now holds 333,689
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cook Meredith sold 500 shares at $73.59 (≈$36.80K) on Oct 13, 2026; now holds 73,424
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Carey Stephen P. sold 2,850 shares at $73.00 (≈$208.05K) on Sep 29, 2026; now holds 168,993
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lalwani Nikhil sold 5,400 shares at $71.00 (≈$383.40K) on Sep 15, 2026; now holds 339,089
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 7, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $266.04M (prior year $211.37M) (+25.9% vs Jun 30, 2025)
- Net income: $24.71M (prior year $8.55M) (+189.1% vs Jun 30, 2025)
- Diluted EPS: $1.05 (prior year $0.36) (+191.7% vs Jun 30, 2025)
Aug 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 27, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 17, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Things to know before you trade ANIP
- Last results release: Aug 7, 2026 (8-K Item 2.02). Previous ones: May 8, 2026, Feb 27, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 6, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.44% (largest 4.5%).
- Liquidity: about 370.66K shares (≈$26.79M) trade per day on average.
- 52-week position: $72.29 vs a range of $69.58–$97.00 (10% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Stephen P. Carey sold 2,850 shares on Sep 29, 2026.
- Latest filings: 8-K Aug 24, 2026; 10-Q Aug 7, 2026; 8-K Aug 7, 2026.
- Share count: 24.42M shares outstanding (Feb 28, 2013), -79.8% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ANIP market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 72.65 | 73.08 | 71.50 | 72.29 | 333.92K |
| Oct 15, 2026 | 71.08 | 73.20 | 71.02 | 72.28 | 241.00K |
| Oct 14, 2026 | 70.54 | 72.31 | 69.90 | 70.16 | 269.20K |
| Oct 13, 2026 | 73.59 | 73.59 | 70.44 | 70.84 | 331.80K |
| Oct 12, 2026 | 74.00 | 74.28 | 72.80 | 73.59 | 318.50K |
| Oct 9, 2026 | 71.87 | 74.43 | 71.25 | 73.89 | 540.80K |
| Oct 8, 2026 | 71.84 | 73.01 | 71.28 | 71.98 | 419.70K |
| Oct 7, 2026 | 71.77 | 72.74 | 71.57 | 71.93 | 438.10K |
| Oct 6, 2026 | 72.99 | 72.99 | 70.80 | 71.52 | 292.00K |
| Oct 5, 2026 | 72.57 | 73.40 | 71.76 | 72.58 | 346.80K |
| Oct 2, 2026 | 73.16 | 73.27 | 71.73 | 72.18 | 300.20K |
| Oct 1, 2026 | 72.54 | 73.96 | 71.64 | 72.96 | 316.70K |
| Sep 30, 2026 | 73.01 | 73.84 | 72.37 | 72.65 | 384.00K |
| Sep 29, 2026 | 74.14 | 74.78 | 72.47 | 72.62 | 328.70K |
| Sep 28, 2026 | 73.72 | 74.92 | 73.05 | 74.83 | 421.70K |
| Sep 25, 2026 | 74.00 | 74.97 | 73.30 | 74.00 | 278.70K |
| Sep 24, 2026 | 74.00 | 75.50 | 73.69 | 74.04 | 368.80K |
| Sep 23, 2026 | 77.00 | 78.86 | 74.21 | 74.43 | 433.60K |
| Sep 22, 2026 | 78.49 | 79.32 | 76.58 | 77.91 | 469.60K |
| Sep 21, 2026 | 75.50 | 79.43 | 75.00 | 78.85 | 579.30K |
About Ani Pharmaceuticals
Ani Pharmaceuticals (ANIP) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PRINCETON, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1023024.
ANIP board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Henry O Gosebruch | Director | Aug 27, 2026 |
| Thomas Haughey | Director | Jun 10, 2026 |
| Nikhil Lalwani | PRESIDENT & CEO | Sep 16, 2026 |
| Matthew J Leonard | Director | Jun 10, 2026 |
| Antonio R Pera | Director | Jun 10, 2026 |
| Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | Mar 2, 2026 |
| Renee P Tannenbaum | Director | Jun 10, 2026 |
| Jeanne Thoma | Director | Sep 14, 2026 |
| Patrick D Walsh | Director | May 13, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Stephen P. Carey | SVP & CFO | Sep 30, 2026 |
| Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sep 14, 2026 |
| Krista Davis | SVP, CHIEF HR OFFICER | Mar 10, 2026 |
| Chad Gassert | SVP - CORP. DEV. & STRATEGY | Mar 2, 2026 |
| Ori Gutwerg | SVP, GENERICS | Aug 11, 2026 |
| Nikhil Lalwani | PRESIDENT & CEO | Sep 16, 2026 |
| Christopher Mutz | HEAD OF RARE DISEASE | Mar 13, 2026 |
| Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | May 13, 2026 |
| Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | Mar 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 29, 2026 | Stephen P. Carey | Sale | 2,850 | $73.00 |
| Sep 29, 2026 | Stephen P. Carey | Sale | 2,850 | $73.00 |
| Sep 29, 2026 | Stephen P. Carey | Sale | 2,850 | $73.00 |
| Sep 29, 2026 | Stephen P. Carey | Sale | 2,850 | $73.00 |
| Sep 15, 2026 | Nikhil Lalwani | Sale | 5,400 | $71.00 |
| Sep 15, 2026 | Nikhil Lalwani | Sale | 5,400 | $71.00 |
| Sep 15, 2026 | Nikhil Lalwani | Sale | 5,400 | $71.00 |
| Sep 15, 2026 | Nikhil Lalwani | Sale | 5,400 | $71.00 |
| Sep 14, 2026 | Meredith Cook | Sale | 500 | $70.79 |
| Sep 14, 2026 | Meredith Cook | Sale | 500 | $70.79 |
| Sep 14, 2026 | Meredith Cook | Sale | 500 | $70.79 |
| Sep 14, 2026 | Meredith Cook | Sale | 500 | $70.79 |
| Sep 11, 2026 | Jeanne Thoma | Sale | 1,000 | $71.53 |
| Sep 11, 2026 | Jeanne Thoma | Sale | 1,000 | $71.53 |
| Sep 11, 2026 | Jeanne Thoma | Sale | 1,000 | $71.53 |
ANIP financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $883.37M | $78.34M | 3.32 | $185.22M |
| Dec 31, 2024 | $614.38M | $-18.52M | -1.04 | $64.02M |
| Dec 31, 2023 | $486.82M | $18.78M | 0.85 | $118.96M |
| Dec 31, 2022 | $316.38M | $-47.90M | -3.05 | $-31.20M |
| Dec 31, 2021 | $216.14M | $-42.60M | -3.40 | $3.32M |
Latest balance sheet: total assets $1.49B, total liabilities $896.90M, cash $360.21M (as of Jun 30, 2026).
ANIP earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 7, 2026 | 8-K Item 2.02 (results) | $78.25 |
| May 8, 2026 | 8-K Item 2.02 (results) | $81.86 |
| Feb 27, 2026 | 8-K Item 2.02 (results) | $73.90 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $84.35 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $88.93 |
| Nov 7, 2025 | 8-K Item 2.02 (results) | $90.43 |
| Sep 8, 2025 | 8-K Item 2.02 (results) | $95.20 |
| Aug 8, 2025 | 8-K Item 2.02 (results) | $81.48 |
| Jul 23, 2025 | 8-K Item 2.02 (results) | $66.90 |
| Jun 4, 2025 | 8-K Item 2.02 (results) | $60.87 |
| May 20, 2025 | 8-K Item 2.02 (results) | $60.64 |
| May 9, 2025 | 8-K Item 2.02 (results) | $66.30 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ANIP
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.